Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors decreased its holdings in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 28.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,107 shares of the company’s stock after selling 1,227 shares during the quarter. Captrust Financial Advisors owned about 0.08% of Invesco Biotechnology & Genome ETF worth $217,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Howe & Rusling Inc. acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $31,000. Creative Financial Designs Inc. ADV raised its stake in shares of Invesco Biotechnology & Genome ETF by 5.6% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after purchasing an additional 299 shares in the last quarter. Massachusetts Wealth Management raised its stake in shares of Invesco Biotechnology & Genome ETF by 7.3% in the 3rd quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock valued at $1,270,000 after purchasing an additional 1,240 shares in the last quarter. Carnegie Investment Counsel acquired a new stake in Invesco Biotechnology & Genome ETF during the third quarter worth about $204,000. Finally, Cetera Investment Advisers raised its stake in Invesco Biotechnology & Genome ETF by 2.1% during the second quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock worth $1,808,000 after acquiring an additional 561 shares during the period.

Invesco Biotechnology & Genome ETF Stock Down 1.0 %

PBE opened at $68.30 on Monday. The firm has a market cap of $275.93 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a fifty-two week low of $59.32 and a fifty-two week high of $72.84. The company’s 50-day moving average price is $69.30 and its 200 day moving average price is $68.48.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.